House of Reps OKs FOI and whistleblower bills

Share this article:
The House of Representatives has approved and sent to the Senate amendments to strengthen the Freedom of Information Act and to provide protection for whistleblowers.

House Oversight and Government Reform Committee chairman Henry Waxman (D-CA), a sponsor of both bills, said their approval was “an important step toward restoring openness and transparency in government. Over the past six years, the Bush administration has done everything it can to operate in secret, to avoid public scrutiny, and to limit congressional oversight.”

The FOI Act Amendments of 2007 (HR 1309), contain provisions to increase public access to government information. Waxman’s background statement on the bill says it will reaffirm the presumption that records should be released to the public if disclosure is allowable under law and the agency cannot foresee a harm from such disclosure.

The amendments would ensure that the 20-day statutory clock for agency responses starts immediately when an agency receives an FOI request and would impose consequences for missing deadlines. The bill strengthens requirements to identify excessive delays and requires agencies to make raw data publicly available.  

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...